Danaher Corp

Most Recent

  • uploads///Portfolio Breakdown of the MFEGX
    Macroeconomic Analysis

    Analyzing the MFS Growth Fund’s 2015 Portfolio

    The information technology, consumer discretionary, and healthcare sectors form the core of the MFS Growth Fund.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Align Technology in August 2017

    Of the 13 analysts covering Align Technology in August 2017, eight rated the company a “strong buy,” and five rated it a “buy.”

    By Margaret Patrick
  • uploads///DHR
    Fund Managers

    Glenview Capital opens new position in Danaher

    Glenview Capital Management added a new position in Danaher Corp. (DHR) in the third quarter. The position accounted for 1.99% of the fund’s total portfolio.

    By Samantha Nielson
  • uploads///ecl pm
    Company & Industry Overviews

    Sterne Agee CRT Rated Ecolab as a ‘Buy’

    Ecolab (ECL) reported fiscal 4Q15 net sales of $3,412.0 million—a fall of 7.3% compared to net sales of $3,680.8 million in fiscal 4Q14.

    By Gabriel Kane
  • uploads///Citadel
    Energy & Utilities

    Must-know highlights of Citadel Advisors’ 2Q14 positions

    Citadel Advisors’ 2Q14 portfolio was worth $73.4 billion, up from $72.5 billion in 1Q14. The total portfolio has over 3000 stocks.

    By Samantha Nielson
  • uploads///recommendations
    Company & Industry Overviews

    What Wall Street Analysts Recommend for Dentsply Sirona

    Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years.

    By Sarah Collins
  • uploads///teeth _
    Company & Industry Overviews

    Align Technology: Analysts Raise Their Target Prices

    On May 25, Berenberg increased its 12-month target price on Align Technology (ALGN) from $312 to $340.

    By Sarah Collins
  • uploads///kyle sterk  unsplash
    Company & Industry Overviews

    ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain

    On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.

    By Sarah Collins
  • uploads///part
    Earnings Report

    Why Did Dover Stock Fall after 1Q16 Earnings Release?

    Dover (DOV), a diversified industrials (XLI) company, released its 1Q16 earnings before the Market opened on April 21, 2016. The stock reacted negatively to the company’s performance.

    By Shannon Black
  • uploads///part
    Company & Industry Overviews

    Danaher Corporation’s Excess Returns Fail to Impress

    Earlier in this series, we looked at Danaher’s return on invested capital on a standalone basis. However, we were only looking at half the story.

    By Shannon Black
  • uploads///ecl pm
    Company & Industry Overviews

    Credit Suisse Raised Ecolab Price Target to $109 per Share

    Ecolab (ECL) reported fiscal 4Q15 net sales of $3,412.0 million, a fall of 7.3% compared to net sales of $3,680.8 million in fiscal 4Q14.

    By Gabriel Kane
  • uploads///danaher environmental margins
    Company & Industry Overviews

    Danaher’s Environmental Segment Is a Cut above the Rest

    Danaher’s Environmental & Applied Solutions unit was responsible for 25% of the company’s sales in 2015.

    By Shannon Black
  • uploads///part
    Company & Industry Overviews

    Introducing Danaher: A Diversified Healthcare Company

    Danaher is a diversified conglomerate with a market cap of ~$56 billion. Its customers are mostly professionals and organizations rather than retail consumers.

    By Shannon Black
  • uploads///danaher adjusted earnings per share
    Earnings Report

    Danaher Stock Jumps as EPS Grows 22.5% on Margin Expansion

    Danaher (DHR) reported adjusted EPS of $0.87, which beat consensus estimates by $0.05. In growth terms, the adjusted EPS was 22.5% YoY.

    By Shannon Black
  • uploads///PLL DHR spread
    Miscellaneous

    The Pall–Danaher Spread is Trading Like a Safe Deal

    A company that has grown largely by acquisition, Danaher is buying Pall, which makes filtration and separation technologies used in life sciences and industrial uses.

    By Brent Nyitray, CFA, MBA
  • uploads///REGN
    Energy & Utilities

    Viking Global buys a new stake in Regeneron Pharmaceuticals

    Viking Global Investors revealed a brand new position valued at around $315 million in Regeneron Pharmaceuticals (REGN) last quarter. The position accounts for 1.32% of Viking’s total portfolio.

    By Samantha Nielson
  • uploads///gks pay
    Earnings Report

    How Does Verifone Compare to Its Peers?

    Verifone Systems (PAY) has achieved a healthy PE (price-to-earnings) ratio of 107.07x.

    By Gabriel Kane
  • uploads///FNF
    Fund Managers

    Glenview Capital increases stake in Fidelity National Financial

    Glenview Capital Management added to its position in Fidelity National Financial (FNF) in the third quarter. Currently, the position accounts for 1.70% of the fund’s total portfolio.

    By Samantha Nielson
  • uploads///part a
    Earnings Report

    Why Danaher Is Relatively Immune from Growth Concerns in China

    Organically, Danaher (DGR) has grown at a CAGR of roughly 10% in China over the last five years. Approximately 50% of the company’s revenues in China are derived from its Diagnostics segment.

    By Shannon Black
  • uploads///gks pay
    Earnings Report

    Verifone Systems Expands in 3Q15

    Verifone Systems (PAY), with a market cap of $3.38 billion, is a leader in providing payment terminals, global payment as a service, and commerce enablement solutions.

    By Gabriel Kane
  • uploads///RTN MS overview
    Earnings Report

    Raytheon’s Missile Systems Segment’s Financial Performance

    Raytheon’s Missile Systems segment had good growth in 4Q14. For the quarter, the net sales were $1,719 million. The net sales were up 5% YoY.

    By Ally Schmidt
  • uploads///ENDP
    Fund Managers

    Glenview Capital raises position in Endo International

    Glenview Capital Management added to its position in Endo International Plc (ENDP) in the third quarter. Currently, the position accounts for 2.02% of the fund’s total portfolio.

    By Samantha Nielson
  • uploads///part
    Company & Industry Overviews

    Dover Fluids: A Brief Overview

    Dover Corporation’s (DOV) Fluids businesses include the Pump Solutions Group (or PSG), which provides pumping solutions to several end markets.

    By Shannon Black
  • uploads///part
    Company & Industry Overviews

    Understanding Dover’s Cash Flow Performance Over Time

    Dover Corporation’s earnings undergo significant swings in changing business cycles. The company’s total sales fell by 10.3% to $7 billion in 2015, mostly due to steep organic declines in the energy segment.

    By Shannon Black
  • uploads///ILMN
    Energy & Utilities

    Why did Halvorsen’s Viking Global boost its position in Illumina?

    Viking Global Investors significantly increased its position in Illumina (ILMN) last quarter. The position, which accounted for 0.88% of Viking’s total 4Q 2013 portfolio, is now the fund’s third largest position, at 5.53% of the 1Q 2014 portfolio.

    By Samantha Nielson
  • uploads///tooth _
    Earnings Report

    Analysts Cut Their Targets for XRAY ahead of Its 1Q18 Results

    Dentsply Sirona, one of the leading dental technology providers in the United States, will announce its 1Q18 earnings results on May 7.

    By Sarah Collins
  • uploads///part
    Earnings Report

    Danaher to Declare Its First Earnings after Fortive Separation

    Danaher Corporation (DHR), which became a diversified healthcare company after its restructuring actions, is slated to declare its 3Q16 earnings on October 20. The consensus Wall Street estimate is for Danaher to post adjusted EPS of $0.83 on sales of ~$4.1 billion.

    By Shannon Black
  • uploads///Part  Prices
    Earnings Report

    How 3M Stock Trended after Its 3Q17 Earnings

    In this pre-earnings series, we’ll look at 3M’s stock performance since its 3Q17 results. On October 24, 2017, 3M announced its 3Q17 earnings and gained 5.9%.

    By Peter Neil
  • uploads///Danaher ana reco
    Company & Industry Overviews

    Analyzing the Performance of Danaher’s Dental Business

    Danaher Corp.’s (DHR) enterprise value is $85.21 billion, and its enterprise-value-to-revenue ratio is 4.42.

    By Kenneth Smith
  • Healthcare

    Must-know: Why did firms report a sharp spike in wages in May?

    Manufacturing growth appears to be steady in the Fifth District. Although new orders declined sharply month-on-month, firms remained upbeat for business prospects.

    By Phalguni Soni
  • uploads///GE
    Industrials

    GE Stock Upgraded by UBS with a ‘Buy,’ $14 Price Target

    Markus Mittermaier, a new analyst at UBS, gave GE stock a “buy” rating yesterday. Previously, UBS offered a “neutral” rating on the stock.

    By Mike Sonnenberg
  • uploads///GE
    Industrials

    Will the New GE CFO Achieve Larry Culp’s Goals?

    Today, GE announced that Carolina Dybeck Happe will take charge as chief financial officer or CFO at GE, replacing from Jamie Miller early next year.

    By Mike Sonnenberg
  • uploads///GE stock
    Earnings Report

    Could Earnings and Culp Continue to Boost GE Stock?

    The third quarter was tough for multinational conglomerate General Electric (GE). Between July 1 and September 30, GE stock lost 15% of its value.

    By Mike Sonnenberg
  • Industrials

    Why do key purchasing managers’ index readings move markets?

    In this series, we’ll focus on the manufacturing PMI issued by three major institutions, measuring manufacturing activity in the U.S.

    By Phalguni Soni
  • uploads///Turnaround
    Financials

    GE Stock Gains, Citigroup Sees Meaningful Turnaround

    On Wednesday, General Electric (GE) stock rose 5.6% after a top Wall Street analyst made some positive remarks about its turnaround efforts.

    By Anirudha Bhagat
  • uploads///Align technolgies
    Company & Industry Overviews

    Align Technology Stock Recovers after Tanking Last Week

    Align Technology stock (ALGN) took a massive hit after Q2 earnings. So what was behind the massive decline, and what’s helping the stock recover?

    By Sushree Mohanty
  • uploads///GE Turbine
    Earnings Report

    Could GE’s Q2 Results Surprise Investors Again?

    General Electric (GE) is slated to report its Q2 results on Wednesday. Let’s look at what analysts expect from the company in the second quarter.

    By Anirudha Bhagat
  • uploads///Chart  Total Debt
    Company & Industry Overviews

    BioPharma Sale to Strengthen General Electric’s Balance Sheet

    In late February, General Electric (GE) made a breakthrough toward reducing its debt obligation and strengthening its balance sheet.

    By Anirudha Bhagat
  • uploads///turbine _
    Energy & Utilities

    GE Wraps Up Q1 with a 37% Gain in Its Stock Price

    Shares of GE have been surging since the beginning of the year and have probably seen the highest gain ever in a first quarter.

    By Anirudha Bhagat
  • uploads///turbine _
    Energy & Utilities

    Why General Electric Stock Plunged ~7% Last Week

    Larry Culp’s latest forecasts for GE’s industrial free cash flow have disappointed GE investors significantly.

    By Anirudha Bhagat
  • uploads///turbine _
    Company & Industry Overviews

    GE Fell ~8% after J.P. Morgan Warned of More Downside Risk

    GE stock extended its declines for the second consecutive day after a JPMorgan Chase analyst warned of more downside risk to the stock.

    By Anirudha Bhagat
  • uploads///turbine _
    Company & Industry Overviews

    GE Soared after Larry Culp Stresses Debt Cut and Dividend Boost

    General Electric (GE) was trading 1.4% higher in pre-market trading today after CEO Larry Culp reassured investors the company would return to a “position of strength.”

    By Anirudha Bhagat
  • uploads///turbine _
    Healthcare

    GE Shares Rose 2.5%, Analysts Turned Bullish on the Stock

    On February 26, General Electric (GE) shares rose after several analysts provided positive comments about its recent deal.

    By Anirudha Bhagat
  • uploads///growth _
    Company & Industry Overviews

    Buffett Missing in Action as GE’s Turnaround Plan Gets Upvote

    General Electric (GE) is up 9.1% today as of 11:50 AM ET. GE has announced that that it has entered a definitive agreement to sell its Biopharma business to Danaher (DHR).

    By Mohit Oberoi, CFA
  • uploads///truck _
    Company & Industry Overviews

    Year-Long GE Transportation-Wabtec Merger Completed

    General Electric (GE) closed the year-long pending merger of its Transportation business unit with Wabtec today.

    By Anirudha Bhagat
  • uploads///turbine _
    Company & Industry Overviews

    GE Stock Rises on Announcement of BioPharma Unit Sale to Danaher

    General Electric (GE) revealed today that it has entered a definitive agreement to sell its BioPharma business to Danaher.

    By Anirudha Bhagat
  • uploads///ILMN
    Company & Industry Overviews

    Analysts Remain Bullish on Illumina Stock

    In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Gross Margin Trend

    Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Geographical Performance

    For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

    By Kenneth Smith
  • uploads///analysis _
    Company & Industry Overviews

    How Johnson & Johnson’s Medical Device Business Stands Now

    Johnson & Johnson’s (JNJ) Medical Devices segment generated net revenues of $6.6 billion in the third quarter, reflecting ~0.2% YoY growth.

    By Daniel Collins
  • uploads///WAT ana reco
    Company & Industry Overviews

    What Waters Corporation’s Valuation Trend Indicates

    In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”

    By Kenneth Smith
  • uploads///Danaher dentalCo spinoff
    Company & Industry Overviews

    A Look at Danaher’s Spin-Off of Its Dental Unit

    In July, Danaher (DHR) announced that it would spin off its Dental segment into a separate public company.

    By Kenneth Smith
  • uploads///rawpixel  unsplash
    Company & Industry Overviews

    Analyzing Perrigo’s Spin-Off of Its Rx Business

    In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.

    By Kenneth Smith
  • uploads///Diagnostics
    Company & Industry Overviews

    A Performance Overview of Roche’s Diagnostics Division

    In July, Roche received the CE Mark for its Accu-Chek Solo micropump system.

    By Daniel Collins
  • uploads///Title
    Earnings Report

    3M’s Stock Performance since Its 4Q17 Earnings

    In a press release, 3M (MMM) said that it plans to announce its 1Q18 earnings on April 24, 2018, before the market opens.

    By Peter Neil
  • uploads///PROJECTIONS
    Company & Industry Overviews

    Reading Dentsply Sirona’s Guidance for 2018

    For fiscal 2018, the company expects its sales to be in the range of $4.2 billion–$4.25 billion.

    By Sarah Collins
  • uploads///leading position
    Company & Industry Overviews

    Why Is Dentsply Sirona So Confident That It Can Gain Market Share?

    Although Dentsply Sirona has given a disappointing performance recently, the company is still confident that it can gain a higher market share going forward.

    By Sarah Collins
  • uploads///ANNUAL LAUNCHES
    Company & Industry Overviews

    Why Innovation Matters to Dentsply Sirona—Now More Than Ever

    Dentsply Sirona has an industry-leading R&D budget with more than 600 scientists and engineers. The company invests $125 million per year on R&D.

    By Sarah Collins
  • uploads///NEW SEGMENT STRUCTUR
    Company & Industry Overviews

    Understanding Dentsply Sirona’s New Organizational Structure

    In 4Q17, Dentsply Sirona (XRAY) started reporting its operations under two segments, after a shift to three segments in fiscal 3Q17.

    By Sarah Collins
  • uploads///Part  Recommendations
    Basic Materials

    Why Analysts Are Positive on W.R. Grace

    In the past six months, the number of analysts covering W.R. Grace (GRA) has fallen from 14 to the present 11.

    By Peter Neil
  • uploads///peter kasprzyk  unsplash
    Company & Industry Overviews

    Why Is Wall Street Still Upbeat on Dentsply Sirona’s Growth Potential in 2018?

    Dentsply Sirona is a leading dental technology, equipment, and consumables provider in the US. But it has been going through some tough times.

    By Sarah Collins
  • uploads///Part  short interestQ DVD
    Company & Industry Overviews

    What Short Interest in Stanley Black & Decker Suggests

    Data from February 28, 2018, shows that Stanley Black & Decker’s (SWK) short interest has fallen since the beginning of 2018.

    By Peter Neil
  • uploads///greyson joralemon  unsplash
    Company & Industry Overviews

    Could Stanley Black & Decker Stock Bounce Back?

    Stanley Black & Decker (SWK) stock has remained low since the beginning of 2018.

    By Peter Neil
  • uploads///How it works
    Company & Industry Overviews

    What’s the Competitive Landscape for Accelerate Diagnostics?

    Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).

    By Kenneth Smith
  • uploads///AXDX market potential
    Company & Industry Overviews

    What’s the Potential Market for Accelerate Diagnostics’ Products?

    Accelerate Diagnostics’ (AXDX) pheno system utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Behind Align Technology’s Key Growth Driver in 2017

    In 3Q17, Align Technology’s (ALGN) Invisalign case volumes shipped to doctors in international markets rose 47.4% on a YoY basis and 6.8% sequentially.

    By Margaret Patrick
  • uploads///leading portfolio
    Company & Industry Overviews

    Developments in Dentsply Sirona’s Digital Dentistry Portfolio

    On September 20, 2017, Dentsply Sirona (XRAY) announced an enhancement to its Galileos Implant software.

    By Sarah Collins
  • uploads///leading portfolio
    Company & Industry Overviews

    Dentsply Sirona’s Newly Launched Cerec Zirconia Meso Block

    In August 2017, Dentsply Sirona (XRAY) launched its Cerec Zirconia Meso Block for creating customized screw-retained crowns.

    By Sarah Collins
  • uploads///MATRX PLUS PATIENT JOURNEY
    Company & Industry Overviews

    Dentsply Sirona’s Dental Sleep Medicine and a Recent Partnership

    Dentsply Sirona (XRAY) and Zephyr Sleep Technologies have entered into a strategic partnership for the treatment of OSA (obstructive sleep apnea).

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Analysts Are Recommending for Dentsply Sirona

    According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Do Analysts Recommend for Dentsply Sirona?

    Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.

    By Sarah Collins
  • uploads///PROJECTIONS
    Company & Industry Overviews

    Discussing Dentsply Sirona’s Updated 2017 Guidance

    Dentsply Sirona made a downward revision to its fiscal 2017 guidance during the company’s 2Q17 earnings results announcement on August 9, 2017.

    By Sarah Collins
  • uploads///REVENUES BY SEGMENT
    Company & Industry Overviews

    Dentsply Sirona’s Technologies Segment Sales Declined in 2Q17

    In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Align Technology Focuses on International Market Strategy

    International market strategy In 2Q17, Align Technology (ALGN) reported 85,400 Invisalign case shipments in international markets, which is YoY (year-over-year) growth of ~37.4% and sequential growth of ~13.6%. This growth was mainly attributed to new customers in the EMEA (Europe, the Middle East, and Africa) and Asia-Pacific markets. If Align Technology continues to demonstrate solid […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Align Technology’s Market Expansion Strategy

    In 1Q17, Align Technology (ALGN) also witnessed a robust rise of around 45.2% in volumes of Invisalign sold in Asia-Pacific markets on a YoY basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Understanding Align Technology’s Growing Position in International Markets

    In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    These Are Align Technologies Key Demand Drivers in North America

    In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Align Technology’s North American Expectations for 2017

    In 1Q17, Align Technology’s (ALGN) Invisalign sales volumes in North American markets rose YoY by 20.3% and QoQ by 8.3%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Align Technology’s Orthodontics Is a Solid Growth Opportunity in 2017

    Align Technology (ALGN) is a medical device provider focused on malocclusion or teeth misalignment condition.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Align Technology’s Robust Revenue Growth Projection for 2017

    For fiscal 2017, Align Technology (ALGN) expects its 2017 revenues to grow operationally in the range of 15%–25% YoY.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Align Technology versus Peers in June 2017: Analyst Recommendations

    For 1Q17, Align Technology (ALGN) reported revenues close to $310.3 million, which represents YoY (year-over-year) growth of around 30.0%.

    By Margaret Patrick
  • uploads///MASS SPECTROMETRY
    Company & Industry Overviews

    What Does Thermo Fisher Want in the Clinical Mass Spectrometry Business?

    Thermo Fisher Scientific (TMO) is focused on strengthening its mass spectrometry business, which is part of its Analytical Instruments segment.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    What Bio-Rad Laboratories Expects from Life Science

    In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Bio-Rad Laboratories’ Profit Margin Expectations in 2017

    On March 13, 2017, Bio-Rad Laboratories (BIO) announced that it expects to reach an EBITDA margin of around 20% by 2020.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017

    On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bio-Rad Laboratories on the Street: Analysts’ Recommendations in May

    In 1Q17, Bio-Rad Laboratories (BIO) reported revenues of ~$500.1 million, which represented a YoY (year-over-year) rise of around 6.1%.

    By Margaret Patrick
  • uploads///revenues by segment
    Earnings Report

    Dentsply Sirona’s New Growth Strategy to Accelerate Digital Dentistry Penetration

    Dentsply Sirona is the largest dental equipment and solutions manufacturer in the United States. Digital dentistry is a megatrend in the market.

    By Sarah Collins
  • uploads///segment revenues
    Earnings Report

    How Did Danaher’s Operating Segments Fare in 4Q16?

    Currently, Danaher (DHR) reports its revenue under four operating segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.

    By Sheldon Krieger
  • uploads///stock
    Earnings Report

    Why Danaher Stock Rose after Its 4Q16 Results

    Danaher Corporation (DHR) announced its 4Q16 and 2016 earnings results before the market opened on January 31, 2017. Let’s take a look.

    By Sheldon Krieger
  • uploads///margin estimates
    Earnings Report

    A Look at Danaher’s 4Q16 Margin Estimates

    In 4Q15, Danaher’s (DHR) adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) was ~$1.4 billion, while its EBITDA margin was 23.3%.

    By Sheldon Krieger
  • uploads///revenue estimates
    Earnings Report

    Behind Danaher’s 4Q16 Revenue Estimates

    Danaher (DHR) reported ~$5.9 billion in consolidated revenue in 4Q15. Analysts expect DHR to report $4.5 billion in 4Q16 revenue.

    By Sheldon Krieger
  • uploads///ANR
    Earnings Report

    How Do Analysts Rate Danaher ahead of Its 4Q16 Results?

    Of the 19 analysts covering Danaher, 15 had given the company “buy” ratings, four had given it “hold” ratings, and none had given it “sell” ratings as of January 12, 2017.

    By Sheldon Krieger
  • uploads///stock price
    Earnings Report

    What Factors Could Drive Danaher Stock in 2017?

    Danaher Corporation (DHR) will announce its 4Q16 earning results before the market opens on January 31, 2017. What should we expect?

    By Sheldon Krieger
  • uploads///ecl pm
    Company & Industry Overviews

    Ecolab Declares a Dividend of $0.37 per Share

    Price movement Ecolab (ECL) has a market cap of $35.4 billion. It rose 0.67% to close at $119.61 per share on December 8, 2016. The stock’s weekly, monthly, and year-to-date (or YTD) price movements were 0.95%, 5.3%, and 5.5%, respectively, on the same day. ECL is trading 3.0% above its 20-day moving average, 2.7% above […]

    By Gabriel Kane
  • uploads///danaher phenomenex
    Earnings Report

    With Phenomenex, Danaher Has an Attractive Consumables Asset

    On October 12, Danaher announced its an agreement to acquire Phenomenex, a privately held manufacturer of separation and purification consumables.

    By Shannon Black
  • uploads///T Rowe Price Blue Chip Growth Fund
    Company & Industry Overviews

    Why the T. Rowe Price Blue Chip Growth Fund Has Had a Rough 2016

    TRBCX has had quite a poor run in 2016 so far. The fund places in the bottom three in the YTD period among the 12 funds in this review.

    By David Ashworth
  • uploads///Portfolio Breakdown of the MFEGX
    Fund Managers

    Inside the MFS Growth Fund Portfolio

    Information technology, consumer discretionary, and healthcare sectors form the core of MFEGX, with a combined 73% of the fund’s net assets.

    By David Ashworth
  • uploads///danaher acquires cepheid
    Healthcare

    How Cepheid Fits Strategically into DHR’s Portfolio

    The acquisition of Cepheid (CPHD) in the strategic sense is a gateway for Danaher (DHR) to breathe life into its limited molecular testing capabilities.

    By Shannon Black
  • uploads///danaher acquires cepheid
    Healthcare

    DHR to Reap $200 Million in Cost Synergies, Revenue through Buy

    Danaher (DHR) says it has identified $100 million in cost synergies and another $100 million in revenues over the next five years.

    By Shannon Black
  • uploads///danaher acquires cepheid
    Healthcare

    What Made Cepheid Attractive to Danaher?

    On September 6, 2016, Danaher (DHR) announced that it has entered into a definitive agreement to acquire Cepheid (CPHD) for $4 billion.

    By Shannon Black
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.